Nanobiotix Q1 Update: Phase 2 NSCLC Data Shows 57.1% Complete Response, Phase 3 Accelerated, Cash Runway to 2029
Summary
Nanobiotix provided its first quarter 2026 operational and financial update. The company reported strong Part 1 data from its Phase 2 CONVERGE study in NSCLC, showing an 85.7% overall response rate and a 57.1% complete response rate in 7 patients, significantly higher than the standard of care. This follows previous announcements of promising data, now with specific efficacy numbers. Additionally, a protocol amendment for the pivotal Phase 3 NANORAY-312 study in head and neck cancer will allow for an earlier final analysis with fewer events. The company confirmed its cash and equivalents, combined with recent offering proceeds, provide sufficient working capital into 2029, reinforcing financial stability.
At the time of this announcement, NBTX was trading at $36.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $4.06 to $57.14. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.